Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer

Glycobiology

Volumn 23, Issue 12, 2013, Pages 1477-1490

  Miwa, Hazuki E ^a   Koba, Wade R ^a   Fine, Eugene J ^a   Giricz, Orsi ^a   Kenny, Paraic A ^a   Stanley, Pamela ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Galectins; Mammary tumors; MGAT3 TCGA

Indexed keywords

ECALECTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; GALECTIN; GALECTIN 10; GALECTIN 13; GALECTIN 14; GALECTIN 2; GALECTIN 4; GALECTIN 7; GALECTIN 8; GLYCAN; MGAT3 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; N GLYCAN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; BETA-1,4-MANNOSYL-GLYCOPROTEIN BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE; POLYSACCHARIDE; VIRUS T ANTIGEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LUNG METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; INBRED MOUSE STRAIN; METABOLISM; MOUSE MAMMARY TUMOR VIRUS; PATHOLOGY;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GALECTINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED STRAINS; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES;

EID: 84887914597     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt075     Document Type: Article

References (60)

1. Ahmad N, Gabius HJ, Andre S, Kaltner H., Sabesan S, Roy R, Liu B., Macaluso F, Brewer CF 2004. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 279:10841-10847.
2. Andre S, Kozar T, Schuberth R., Unverzagt C, Kojima S, Gabius HJ 2007. Substitutions in the N-glycan core as regulators of biorecognition: The case of core-fucose and bisecting GlcNAc moieties. Biochemistry. 46:6984-6995.
3. Andre S, Unverzagt C, Kojima S., Frank M, Seifert J, Fink C., Kayser K, von der Lieth CW, Gabius HJ. 2004. Determination of modulation of ligand properties of synthetic complex-type biantennary N-glycans by introduction of bisecting GlcNAc in silico, in vitro and in vivo. Eur J Biochem. 271: 118-134.
4. Banh A, Zhang J, Cao H., Bouley DM, Kwok S, Kong C, Giaccia A.J., Koong AC, Le QT 2011. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71:4423-4431.
5. Basu GD, Pathangey LB, Tinder T.L., Lagioia M., Gendler SJ, Mukherjee P. 2004. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2:632-642.
6. Berger T, Cheung CC, Elia A.J., Mak TW 2010. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci USA. 107:2995-3000.
7. Boscher C, Dennis JW, Nabi IR 2011. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol. 23:383-392.
8. Brewer CF, Miceli MC, Baum LG 2002. Clusters, bundles, arrays and lattices: Novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol. 12:616-623.
9. Brisson JR, Carver JP 1983. Solution conformation of asparagine-linked oligo-saccharides: Alpha(1-2)-, alpha(1-3)-, beta(1-2)-, and beta(1-4)-linked units. Biochemistry. 22:3671-3680.
10. Campbell C, Stanley P. 1984. A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GlcNAc: glycopeptide beta-4-N-acetylglucosaminyltransferase III activity. J Biol Chem. 259:13370-13378.
11. Cramer EP, Glenthoj A, Hager M., Juncker-Jensen A, Engelholm LH, Santoni-Rugiu E, Lund L.R., Laerum OD, Cowland JB, Borregaard N. 2012. No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer. PLoS One. 7:e39646.
12. Croci DO, Salatino M, Rubinstein N., Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui J.M., Toscano MA, Domaica CI, et al 2012. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogen-esis and tumorigenesis in Kaposi's sarcoma. J Exp Med. 209:1985-2000.
13. Dalotto-Moreno T., Croci DO, Cerliani J.P., Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, Stupirski JC, Mazal D, Osinaga E., Toscano MA, et al 2013. Targeting galectin-1 overcomes breast cancer-associated immunosup-pression and prevents metastatic disease. Cancer Res. 73:1107-1117.
14. Davie SA, Maglione JE, Manner C.K., Young D., Cardiff RD, MacLeod CL, Ellies LG 2007. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 16:193-201.
15. Dennis JW, Brewer CF 2013. Density-dependent lectin-glycan interactions as a paradigm for conditional regulation by posttranslational modifications. Mol Cell Proteomics. 12:913-920.
16. Dennis JW, Lau KS, Demetriou M, Nabi IR 2009. Adaptive regulation at the cell surface by N-glycosylation. Traffic. 10:1569-1578.
17. Di Lella S., Sundblad V, Cerliani J.P., Guardia CM, Estrin DA, Vasta GR, Rabinovich GA 2011. When galectins recognize glycans: From biochemistry to physiology and back again. Biochemistry. 50:7842-7857.
18. Eude-Le Parco I, Gendronneau G, Dang T, Delacour D, Thijssen VL, Edelmann W, Peuchmaur M, Poirier F. 2009. Genetic assessment of the importance of galectin- 3 in cancer initiation, progression, and dissemination in mice. Glycobiology. 19:68-75.
19. Gatenby RA, Gillies RJ 2004. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891-899.
20. Guo H, Nairn A, dela Rosa M, Nagy T, Zhao S., Moremen K, Pierce M. 2012. Transcriptional regulation of the protocadherin beta cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. J Biol Chem. 287:24941-24954.
21. Guy CT, Cardiff RD, Muller WJ 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol. 12:954-961.
22. Gyorffy B, Lanczky A, Eklund A.C., Denkert C., Budczies J, Li Q, Szallasi Z. 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725-731.
23. Haga Y, Ishii K, Suzuki T. 2011. N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4. J Biol Chem. 286: 31320-31327.
24. Houzelstein D, Goncalves IR, Orth A, Bonhomme F., Netter P. 2008. Lgals6, a 2-million-year-old gene in mice: A case of positive Darwinian selection and presence/absence polymorphism. Genetics. 178:1533-1545.
25. Irie A, Yamauchi A, Kontani K., Kihara M, Liu D, Shirato Y., Seki M, Nishi N, Nakamura T., Yokomise H., et al 2005. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 11: 2962-2968.
26. Iyengar P, Espina V, Williams T.W., Lin Y., Berry D, Jelicks LA, Lee H, Temple K., Graves R, Pollard J., et al 2005. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 115:1163-1176.
27. Joyce JA, Pollard JW 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer. 9:239-252.
28. Kitagawa T, Tsuruhara Y, Hayashi M., Endo T, Stanbridge EJ 1995. A tumor-associated glycosylation change in the glucose transporter GLUT1 controlled by tumor suppressor function in human cell hybrids. J Cell Sci. 108(Pt 12):3735-3743.
29. Koressaar T, Remm M. 2007. Enhancements and modifications of primer design program Primer3. Bioinformatics. 23:1289-1291.
30. Landskroner-Eiger S., Qian B, Muise E.S., Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y., Pollard JW, Scherer PE 2009. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res. 15:3265-3276.
31. Lau KS, Dennis JW 2008. N-Glycans in cancer progression. Glycobiology. 18:750-760.
32. Lau KS, Partridge EA, Grigorian A, Silvescu C.I., Reinhold VN, Demetriou M, Dennis JW 2007. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 129: 123-134.
33. Leffler H, Carlsson S, Hedlund M., Qian Y, Poirier F. 2004. Introduction to galectins. Glycoconj J. 19:433-440.
34. Li Q, Birkbak NJ, Gyorffy B, Szallasi Z., Eklund AC 2011. Jetset: Selecting the optimal microarray probe set to represent a gene. BMC Bioinform. 12:474.
35. Miwa HE, Song Y, Alvarez R., Cummings RD, Stanley P. 2012. The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj J. 29: 609-618.
36. Network CGA. 2012. Comprehensive molecular portraits of human breast tumours. Nature. 490:61-70.
37. Nio-Kobayashi J., Takahashi-Iwanaga H, Iwanaga T. 2009. Immunohisto-chemical localization of six galectin subtypes in the mouse digestive tract. J Histochem Cytochem. 57:41-50.
38. Nobumoto A, Nagahara K, Oomizu S., Katoh S, Nishi N, Takeshita K., Niki T, Tominaga A, Yamauchi A., Hirashima M. 2008. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 18:735-744.
39. North SJ, Huang HH, Sundaram S, Jang-Lee J, Etienne A.T., Trollope A., Chalabi S, Dell A, Stanley P., Haslam SM 2010. Glycomics profiling of Chinese hamster ovary cell glycosylation mutants reveals N-glycans of a novel size and complexity. J Biol Chem. 285:5759-5775.
40. Ohtsubo K, Takamatsu S, Minowa M.T., Yoshida A., Takeuchi M, Marth JD 2005. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 123:1307-1321.
41. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M., Nabi IR, Wrana JL, Dennis JW 2004. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 306:120-124.
42. Patnaik SK, Potvin B, Carlsson S., Sturm D, Leffler H, Stanley P. 2006. Complex Nglycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. Glycobiology. 16:305-317.
43. Priatel JJ, Sarkar M, Schachter H., Marth JD 1997. Isolation, characterization and inactivation of the mouse Mgat3 gene: The bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction. Glycobiology. 7:45-56.
44. Seelenmeyer C, Stegmayer C, Nickel W. 2008. Unconventional secretion of fibroblast growth factor 2 and galectin-1 does not require shedding of plasma membrane-derived vesicles. FEBS Lett. 582:1362-1368.
45. Seelenmeyer C, Wegehingel S, Tews I., Kunzler M, Aebi M, Nickel W. 2005. Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1. J Cell Biol. 171:373-381.
46. Song Y, Aglipay JA, Bernstein J.D., Goswami S., Stanley P. 2010. The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res. 70:3361-3371.
47. Stanley P, Caillibot V, Siminovitch L. 1975. Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cell. Cell. 6:121-128.
48. Thijssen VL, Barkan B, Shoji H., Aries IM, Mathieu V, Deltour L, Hackeng T.M., Kiss R., Kloog Y, Poirier F., et al 2010. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70: 6216-6224.
49. Thijssen VL, Postel R, Brandwijk R.J., Dings RP, Nesmelova I, Satijn S, Verhofstad N., Nakabeppu Y, Baum LG, Bakkers J., et al 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 103:15975-15980.
50. Untergasser A, Cutcutache I, Koressaar T., Ye J, Faircloth BC, Remm M, Rozen SG 2012. Primer3-new capabilities and interfaces. Nucleic Acids Res. 40:e115.
51. van de Vijver M. 2005. Gene-expression profiling and the future of adjuvant therapy. Oncologist. 10 Suppl 2:30-34.
52. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999-2009.
53. Varki A, Cummings RD, Esko J.D., Freeze HH, Stanley P, Bertozzi CR, Hart G.W., Etlzler ME 2009. Essentials of Glycobiology. 2nd edition Cold Spring Harbor laboratory Press: New York, NY.
54. Wang Y, Klijn JG, Zhang Y, Sieuwerts A.M., Look MP, Yang F, Talantov D, Timmermans M., Meijer-van Gelder ME, Yu J., et al. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671-679.
55. Wang H, Yang H, Shivalila C.S., Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. 2013. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 153:910-918.
56. Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body. J Gen Physiol. 8:519-530.
57. Williams TM, Medina F, Badano I., Hazan RB, Hutchinson J, Muller WJ, Chopra N.G., Scherer PE, Pestell RG, Lisanti MP 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metallopro-teinase (MMP-2/9) secretion. J Biol Chem. 279:51630-51646.
58. Yang RY, Yu L, Graham J.L., Hsu DK, Lloyd KC, Havel PJ, Liu FT 2011. Ablation of a galectin preferentially expressed in adipocytes increases lipoly-sis, reduces adiposity, and improves insulin sensitivity in mice. Proc Natl Acad Sci USA. 108:18696-18701.
59. Ying H, Kimmelman AC, Lyssiotis C.A., Hua S., Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H., Coloff JL, et al 2012. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 149:656-670.
60. Young CD, Lewis AS, Rudolph M.C., Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R., Abel ED, Anderson SM 2011. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 6:e23205.